Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Circ Res ; 100(11): 1605-14, 2007 Jun 08.
Article in English | MEDLINE | ID: mdl-17478725

ABSTRACT

Store-operated Ca(2+) entry was investigated in isolated mouse sinoatrial nodes (SAN) dissected from right atria and loaded with Ca(2+) indicators. Incubation of the SAN in Ca(2+)-free solution caused a substantial decrease in resting intracellular Ca(2+) concentration ([Ca(2+)](i)) and stopped pacemaker activity. Reintroduction of Ca(2+) in the presence of cyclopiazonic acid (CPA), a sarcoplasmic reticulum Ca(2+) pump inhibitor, led to sustained elevation of [Ca(2+)](i), a characteristic of store-operated Ca(2+) channel (SOCC) activity. Two SOCC antagonists, Gd(3+) and SKF-96365, inhibited 72+/-8% and 65+/-8% of this Ca(2+) influx, respectively. SKF-96365 also reduced the spontaneous pacemaker rate to 27+/-4% of control in the presence of CPA. Because members of the transient receptor potential canonical (TRPC) gene family may encode SOCCs, we used RT-PCR to examine mRNA expression of the 7 known mammalian TRPC isoforms. Transcripts for TRPC1, 2, 3, 4, 6, and 7, but not TRPC5, were detected. Immunohistochemistry using anti-TRPC1, 3, 4, and 6 antibodies revealed positive labeling in the SAN region and single pacemaker cells. These results indicate that mouse SAN exhibits store-operated Ca(2+) activity which may be attributable to TRPC expression, and suggest that SOCCs may be involved in regulating pacemaker firing rate.


Subject(s)
Biological Clocks/physiology , Calcium Channels/metabolism , Calcium Signaling/physiology , Calcium/metabolism , Sinoatrial Node/metabolism , TRPC Cation Channels/metabolism , Action Potentials/drug effects , Action Potentials/physiology , Adrenergic beta-Agonists/pharmacology , Animals , Anti-Arrhythmia Agents/pharmacology , Biological Clocks/drug effects , Biological Clocks/genetics , Calcium Channel Blockers/pharmacology , Calcium Channels/drug effects , Calcium Channels/genetics , Calcium Signaling/drug effects , Calcium Signaling/genetics , Enzyme Inhibitors/pharmacology , Gene Expression/drug effects , In Vitro Techniques , Male , Mice , Mice, Inbred BALB C , Protein Isoforms/drug effects , Protein Isoforms/genetics , Protein Isoforms/metabolism , RNA, Messenger/biosynthesis , Ryanodine/pharmacology , Sarcoplasmic Reticulum/drug effects , Sarcoplasmic Reticulum/metabolism , Sinoatrial Node/cytology , Sinoatrial Node/drug effects , TRPC Cation Channels/drug effects , TRPC Cation Channels/genetics
2.
Cell ; 128(5): 947-59, 2007 Mar 09.
Article in English | MEDLINE | ID: mdl-17350578

ABSTRACT

During heart development the second heart field (SHF) provides progenitor cells for most cardiomyocytes and expresses the homeodomain factor Nkx2-5. We now show that feedback repression of Bmp2/Smad1 signaling by Nkx2-5 critically regulates SHF proliferation and outflow tract (OFT) morphology. In the cardiac fields of Nkx2-5 mutants, genes controlling cardiac specification (including Bmp2) and maintenance of the progenitor state were upregulated, leading initially to progenitor overspecification, but subsequently to failed SHF proliferation and OFT truncation. In Smad1 mutants, SHF proliferation and deployment to the OFT were increased, while Smad1 deletion in Nkx2-5 mutants rescued SHF proliferation and OFT development. In Nkx2-5 hypomorphic mice, which recapitulate human congenital heart disease (CHD), OFT anomalies were also rescued by Smad1 deletion. Our findings demonstrate that Nkx2-5 orchestrates the transition between periods of cardiac induction, progenitor proliferation, and OFT morphogenesis via a Smad1-dependent negative feedback loop, which may be a frequent molecular target in CHD.


Subject(s)
Bone Morphogenetic Proteins/metabolism , Feedback, Physiological , Homeodomain Proteins/metabolism , Multipotent Stem Cells/cytology , Myocardium/cytology , Myocytes, Cardiac/cytology , Smad1 Protein/metabolism , Transcription Factors/metabolism , Transforming Growth Factor beta/metabolism , Animals , Bone Morphogenetic Protein 2 , Cell Proliferation , DNA, Complementary , Embryo, Mammalian , Heart/embryology , Heart Defects, Congenital/genetics , Heart Defects, Congenital/metabolism , Homeobox Protein Nkx-2.5 , Homeodomain Proteins/genetics , Humans , LIM-Homeodomain Proteins , Mice , Multipotent Stem Cells/metabolism , Myocytes, Cardiac/metabolism , Oligonucleotide Array Sequence Analysis , Phenotype , Transcription Factors/genetics
3.
J Mol Cell Cardiol ; 37(5): 979-87, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15522275

ABSTRACT

In response to pressure-overload, cardiac function deteriorates and may even progress to fulminant heart failure and death. Here we questioned if genetic enhancement of left ventricular (LV) contractility protects against pressure-overload. Transgenic (TG) mice with cardiac-restricted overexpression (66-fold) of the alpha(1A)-adrenergic receptor (alpha(1A)-AR) and their non-TG (NTG) littermates, were subjected to transverse aorta constriction (TAC)-induced pressure-overload for 12 weeks. TAC-induced hypertrophy was similar in the NTG and TG mice but the TG mice were less likely to die of heart failure compared to the non-TG animals (P <0.05). The hypercontractile phenotype of the TG mice was maintained over the 12-week period following TAC with LV fractional shortening being significantly greater than in the NTG mice (42+/-2 vs 29+/-1%, P <0.01). In the TG animals, 11-week beta-AR-blockade with atenolol neither induced hypertrophy nor suppressed the hypercontractile phenotype. The hypertrophic response to pressure-overload was not altered by cardiac alpha(1A)-AR overexpression. Moreover, the inotropic phenotype of alpha(1A)-AR overexpression was well maintained under conditions of pressure overload. Although the functional decline in contractility with pressure overload was similar in the TG and NTG animals, given that contractility was higher before TAC in the TG mice, their LV function was better preserved and heart failure deaths were fewer after induction of pressure overload.


Subject(s)
Genetic Enhancement , Hypertrophy, Left Ventricular/prevention & control , Myocardial Contraction/genetics , Receptors, Adrenergic, alpha-1/genetics , Actins/genetics , Animals , Antihypertensive Agents/pharmacology , Atenolol/pharmacology , Atrial Natriuretic Factor/genetics , Blood Pressure/drug effects , Blood Pressure/genetics , Blood Pressure/physiology , Cardiac Myosins/genetics , Cardiac Output, Low/etiology , Cardiac Output, Low/genetics , Cardiac Output, Low/prevention & control , Constriction , Electrocardiography , Gene Expression/genetics , Hypertrophy, Left Ventricular/etiology , Hypertrophy, Left Ventricular/genetics , Mice , Mice, Transgenic , Myocardial Contraction/physiology , Myosin Light Chains/genetics , Receptors, Adrenergic, alpha-1/physiology , Ventricular Function
4.
J Cell Physiol ; 197(1): 53-60, 2003 Oct.
Article in English | MEDLINE | ID: mdl-12942540

ABSTRACT

Overexpression of IGF-1 in C2C12 myoblasts causes hypertrophy when myoblasts fuse to form myotubes, a response that requires elevated intracellular calcium. We show that myoblasts contain a store-operated Ca2+ channel (SOCC) whose activity is enhanced with IGF-1 overexpression. A membrane protein, CD20, can cause Ca2+ entry, which is increased by IGF-1. We therefore tested whether CD20 mediates the SOCC activity in myoblasts. An antibody to the extracellular loop of CD20 detected a protein in myoblasts and this antibody also inhibited Ca2+ entry through SOCC. Overexpression of CD20 in myoblasts increased SOCC activity. However, we could not detect mRNA for CD20 in myoblasts and an antibody to the intracellular C-terminus of CD20 was unable to detect CD20 in these cells. These studies demonstrate that CD20 is a novel SOCC or modulates SOCC activity. However, the SOCC activity observed in C2C12 myoblasts is mediated not by CD20, but by a CD20-like protein. Activation of this SOCC may contribute to IGF-1-induced hypertrophy in these cells.


Subject(s)
Antigens, CD20/metabolism , Calcium Channels/metabolism , Insulin-Like Growth Factor I/metabolism , Muscle, Skeletal/metabolism , Myoblasts/metabolism , Animals , Blotting, Northern , Blotting, Western , Calcium/metabolism , Cells, Cultured , Humans , Mice , Muscle, Skeletal/cytology , RNA, Messenger/analysis , Reverse Transcriptase Polymerase Chain Reaction
5.
Circ Res ; 90(6): 678-81, 2002 Apr 05.
Article in English | MEDLINE | ID: mdl-11934835

ABSTRACT

Many factors have been shown to be involved in the development of hyperplasic lesions of vessels, but the role of extracellular nucleotides remains largely unknown. The presence of P2Y and P2X nucleotide receptors on arterial endothelial and smooth muscle cells suggests a potential role for nucleotides in the vessel pathophysiology. Although the role of P2X in physiology of vessels is well documented, that of P2Y is not completely understood. We recently demonstrated that extracellular nucleotides, and particularly UTP, induced migration of cultured arterial smooth muscle cells (ASMCs). This migration is dependent on osteopontin expression and involves the Rho and mitogen-activated protein (MAP) kinase pathways. An important question is to determine the specific role of the different P2Y receptors of rat ASMCs in the UTP-induced migration process. Therefore, we first quantified mRNA levels of P2Y(2), P2Y(4), and P2Y(6) nucleotide receptors in cultured rat ASMCs by a competitive RT-PCR approach and demonstrated that P2Y(2) is the most highly expressed among these receptors potentially involved in the UTP-mediated response. In addition to UTP, UDP also induced ASMC migration even when UTP regeneration was inhibited, suggesting the involvement of UDP receptor P2Y(6). Moreover, suramin, a specific antagonist of rat P2Y(2) receptor, acted as an inhibitor of UTP-induced migration. Taken together, these results suggest a prominent role for the UTP receptor, P2Y(2), and for the UDP receptor, P2Y(6), in UTP-induced rat ASMC migration.


Subject(s)
Cell Movement/physiology , Muscle, Smooth, Vascular/physiology , Receptors, Purinergic P2/physiology , Animals , Cell Movement/drug effects , Cells, Cultured , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , Muscle, Smooth, Vascular/cytology , Purinergic P2 Receptor Agonists , Purinergic P2 Receptor Antagonists , Rats , Rats, Wistar , Receptors, Purinergic P2Y2 , Reverse Transcriptase Polymerase Chain Reaction , Suramin/pharmacology , Uridine Diphosphate/pharmacology , Uridine Triphosphate/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...